(Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

The sale of 23andMe was finalized this week, following the company filing for bankruptcy in March. The sale was previously approved by a judge. The company was purchased by the nonprofit TTAM Research ...

23andMe’s interim chief executive Joseph Selsavage told lawmakers on Tuesday that 1.9 million people, or about 15% of its customer base, have requested their genetic data be deleted from the company’s ...

Me on Sunday filed for bankruptcy in the U.S. after struggling with weak demand for its ancestry testing kits and a 2023 data ...

NEW YORK (AP) — Anne Wojcicki’s bid to buy 23andMe, the genetic testing company she cofounded nearly 20 years ago, has received the court greenlight. Silicon Valley county sues Meta, alleging it made ...

FIRST ON FOX: Republican senators John Cornyn and Chuck Grassley and Democratic Sen. Amy Klobuchar are rolling out a bipartisan measure to protect sensitive genetic data in response to privacy ...

The bidding competition over 23andMe may not be over. The founder of 23andMe, Anne Wojcicki, has asked a federal bankruptcy court judge to reopen an auction for the genetic testing company, saying she ...

Bankrupt 23andMe is facing a lawsuit over its plans to sell customer genetic information. Twenty-seven states and the District of Columbia took legal action this week against 23andMe in the U.S.